CAR-T cell therapy (Timmune Biotech)

N/A

Report date: 2024/11/21 20:00:04

Base Information

Drug NameCAR-T cell therapy (Timmune Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionProgrammed death-ligand 1 blockersT lymphocyte replacements

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsMultiple MyelomaLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesTianjin Timmune Biotech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTianjin Timmune Biotech Inc

Active IndicationsN/A

Inactive IndicationsMultiple MyelomaLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A